FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361009216> ?p ?o ?g. }

• W4361009216 endingPage "502" @default.
• W4361009216 startingPage "494" @default.
• W4361009216 abstract "Evaluate the real-world costs over two years and costs by site of care for ocrelizumab (OCR), natalizumab (NTZ), and alemtuzumab (ATZ) in patients with multiple sclerosis (MS).This retrospective study used HealthCore Integrated Research Database and included continuously enrolled adults with MS initiating OCR, NTZ, and ATZ between April 2017 and July 2019 (i.e. patient identification period). Annual total cost of care (pharmacy and medical costs) was evaluated for the first- and second-year of follow-up, further stratified by site of care. Costs were measured using health plan allowed amount and adjusted to 2019 US dollars. Sensitivity analyses were conducted in patients who completed yearly dosing schedule according to Food and Drug Administration approved prescribing information.Overall, 1,058, 166, and 46 patients were included in OCR, NTZ, and ATZ cohorts, respectively. Mean (standard deviation [SD]) total cost of care during first- and second-year follow-up were $125,597 ($72,274) and $109,618 ($75,085) for OCR, $117,033 ($57,102) and $106,626 ($54,872) for NTZ, and $179,809 ($97,530) and $108,636 ($77,973) for ATZ. Infusible drug cost was the main driver in all three cohorts accounting for >78% of the total costs. Annual total cost of care increased substantially after patients started/switched to infusible DMTs. Across site of care, hospital outpatient infusion was common (OCR 58%, NTZ 37%, ATZ 49%) and expensive followed by physician office infusion (OCR 28%, NTZ 40%, ATZ 16%); home infusion was the least common (<10%) and least expensive.The results were limited to commercially insured patients (specifically those with Anthem-affiliated health plans).Real-world costs increased after patients started/switched to infusible DMTs. Drug cost is the main driver for the total costs, which varied substantially by site of care. Controlling drug cost markups and using home setting for infusion can reduce costs in the treatment of MS patients.Ocrelizumab (OCR), natalizumab (NTZ), and alemtuzumab (ATZ) are infusible drugs to treat patients with multiple sclerosis (MS). We did a study to understand the costs of these infusible MS drugs in real-world settings by analyzing a patients’ pharmacy and medical claims database. A total of 1,058 patients were included. We found that the annual total costs increased substantially after patients started to use these infusible MS drugs. Specifically, the average first- and second-year total costs for patients were $125,597 and $109,618 for OCR, $117,033 and $106,626 for NTZ, and $179,809 and $108,636 for ATZ, respectively. We also found that the cost of the drug itself is the main driver for the overall healthcare spending, accounting for >78% of the total costs. Additionally, we found that the cost varies depending on where patients receive these infusible MS drugs, and generally speaking, infusions received from hospital outpatient settings would be more expensive than received from home settings. In summary, this study showed that the real-world costs of these infusible MS drugs are very high. Shifting patients away from more costly hospital outpatient departments or using MS drugs that do not require infusion resources (e.g. oral/self-injectable) may help reduce the overall healthcare spending on MS." @default.
• W4361009216 created "2023-03-30" @default.
• W4361009216 creator A5019339894 @default.
• W4361009216 creator A5030173017 @default.
• W4361009216 creator A5056278530 @default.
• W4361009216 creator A5056720424 @default.
• W4361009216 creator A5064205043 @default.
• W4361009216 creator A5070821839 @default.
• W4361009216 creator A5088161063 @default.
• W4361009216 creator A5091357745 @default.
• W4361009216 date "2023-04-03" @default.
• W4361009216 modified "2023-10-18" @default.
• W4361009216 title "Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies" @default.
• W4361009216 cites W2014094373 @default.
• W4361009216 cites W2067673653 @default.
• W4361009216 cites W2121656227 @default.
• W4361009216 cites W2734537819 @default.
• W4361009216 cites W2914096077 @default.
• W4361009216 cites W2983366396 @default.
• W4361009216 cites W3017665512 @default.
• W4361009216 cites W3132700063 @default.
• W4361009216 cites W3157239883 @default.
• W4361009216 doi "https://doi.org/10.1080/13696998.2023.2194185" @default.
• W4361009216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36970763" @default.
• W4361009216 hasPublicationYear "2023" @default.
• W4361009216 type Work @default.
• W4361009216 citedByCount "0" @default.
• W4361009216 crossrefType "journal-article" @default.
• W4361009216 hasAuthorship W4361009216A5019339894 @default.
• W4361009216 hasAuthorship W4361009216A5030173017 @default.
• W4361009216 hasAuthorship W4361009216A5056278530 @default.
• W4361009216 hasAuthorship W4361009216A5056720424 @default.
• W4361009216 hasAuthorship W4361009216A5064205043 @default.
• W4361009216 hasAuthorship W4361009216A5070821839 @default.
• W4361009216 hasAuthorship W4361009216A5088161063 @default.
• W4361009216 hasAuthorship W4361009216A5091357745 @default.
• W4361009216 hasBestOaLocation W43610092161 @default.
• W4361009216 hasConcept C104863432 @default.
• W4361009216 hasConcept C118552586 @default.
• W4361009216 hasConcept C126322002 @default.
• W4361009216 hasConcept C147789679 @default.
• W4361009216 hasConcept C162324750 @default.
• W4361009216 hasConcept C175444787 @default.
• W4361009216 hasConcept C182299520 @default.
• W4361009216 hasConcept C185592680 @default.
• W4361009216 hasConcept C187212893 @default.
• W4361009216 hasConcept C194828623 @default.
• W4361009216 hasConcept C2777288759 @default.
• W4361009216 hasConcept C2778843634 @default.
• W4361009216 hasConcept C2779134260 @default.
• W4361009216 hasConcept C2779338263 @default.
• W4361009216 hasConcept C2780640218 @default.
• W4361009216 hasConcept C2780653079 @default.
• W4361009216 hasConcept C2781004633 @default.
• W4361009216 hasConcept C512399662 @default.
• W4361009216 hasConcept C71924100 @default.
• W4361009216 hasConcept C72092618 @default.
• W4361009216 hasConceptScore W4361009216C104863432 @default.
• W4361009216 hasConceptScore W4361009216C118552586 @default.
• W4361009216 hasConceptScore W4361009216C126322002 @default.
• W4361009216 hasConceptScore W4361009216C147789679 @default.
• W4361009216 hasConceptScore W4361009216C162324750 @default.
• W4361009216 hasConceptScore W4361009216C175444787 @default.
• W4361009216 hasConceptScore W4361009216C182299520 @default.
• W4361009216 hasConceptScore W4361009216C185592680 @default.
• W4361009216 hasConceptScore W4361009216C187212893 @default.
• W4361009216 hasConceptScore W4361009216C194828623 @default.
• W4361009216 hasConceptScore W4361009216C2777288759 @default.
• W4361009216 hasConceptScore W4361009216C2778843634 @default.
• W4361009216 hasConceptScore W4361009216C2779134260 @default.
• W4361009216 hasConceptScore W4361009216C2779338263 @default.
• W4361009216 hasConceptScore W4361009216C2780640218 @default.
• W4361009216 hasConceptScore W4361009216C2780653079 @default.
• W4361009216 hasConceptScore W4361009216C2781004633 @default.
• W4361009216 hasConceptScore W4361009216C512399662 @default.
• W4361009216 hasConceptScore W4361009216C71924100 @default.
• W4361009216 hasConceptScore W4361009216C72092618 @default.
• W4361009216 hasIssue "1" @default.
• W4361009216 hasLocation W43610092161 @default.
• W4361009216 hasLocation W43610092162 @default.
• W4361009216 hasOpenAccess W4361009216 @default.
• W4361009216 hasPrimaryLocation W43610092161 @default.
• W4361009216 hasRelatedWork W1532617462 @default.
• W4361009216 hasRelatedWork W2980318299 @default.
• W4361009216 hasRelatedWork W3030177861 @default.
• W4361009216 hasRelatedWork W3036083494 @default.
• W4361009216 hasRelatedWork W3047603382 @default.
• W4361009216 hasRelatedWork W3198188212 @default.
• W4361009216 hasRelatedWork W3206160011 @default.
• W4361009216 hasRelatedWork W4280641620 @default.
• W4361009216 hasRelatedWork W4283511960 @default.
• W4361009216 hasRelatedWork W4361009216 @default.
• W4361009216 hasVolume "26" @default.
• W4361009216 isParatext "false" @default.
• W4361009216 isRetracted "false" @default.
• W4361009216 workType "article" @default.